Avalo Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
Avalo Therapeutics, a clinical-stage biotechnology firm dedicated to IL-1β based therapies for immune-mediated inflammatory diseases, announced a proposed underwritten public offering of its common stock and pre-funded warrants. The company plans to use the proceeds to further develop its lead asset, abdakibart, including Phase 3 topline data relea…